TY - JOUR
T1 - Final opinion on the safety of breast implants in relation to anaplastic large cell lymphoma
T2 - Report of the scientific committee on health, emerging and environmental risks (SCHEER)
AU - SCHEER
AU - De Jong, Wim H.
AU - Panagiotakos, Demosthenes
AU - Proykova, Ana
AU - Samaras, Theodoros
AU - Clemens, Mark W.
AU - De Jong, Daphne
AU - Hopper, Ingrid
AU - Rakhorst, Hinne A.
AU - Santanelli di Pompeo, Fabio
AU - Turner, Suzanne D.
N1 - Funding Information:
SCHEER considers that there is a moderate weight of evidence for a causal relationship between textured breast implants and BIA-ALCL. As BIA-ALCL is a low incidence disease, developing and maintaining global networks with cross-country communication is of major importance to better understand its pathogenesis and spread to the population. Also, current registries should collaborate and strengthen their networks as well as aim to inform. This should be encouraged and actively supported by providing funding and infrastructural support.
Publisher Copyright:
© 2021
PY - 2021/10
Y1 - 2021/10
N2 - The Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) was requested by the European Commission (EC) to provide a scientific opinion on the safety of breast implants in relation to anaplastic large cell lymphoma (ALCL). There are several types of textured breast implants; surface textures of breast implants are not all manufactured in the same way, and breast implants with diverse surface textures may also present different benefits. The magnitude of the risk per type of textured implant is difficult to establish due to the low incidence of the breast implants associated anaplastic large cell lymphoma (BIA-ALCL). Therefore, risk assessments per implant type are needed. Overall SCHEER considers that there is a moderate weight of evidence for a causal relationship between textured breast implants and BIA-ALCL, particularly in relation to implants with an intermediate to high surface roughness.The pathogenic mechanisms are not fully elucidated; current hypotheses include genetic drivers, chronic inflammation resulting either from bacterial contamination, shell shedding of particulates, or shell surface characteristics leading to friction, or by implant associated reactive compounds. Reporting of new BIA-ALCL cases by the national clinical registries is critically important to obtain a better estimate of the risk of BIA-ALCL for patients with a breast implant.
AB - The Scientific Committee on Health, Environmental and Emerging Risks (SCHEER) was requested by the European Commission (EC) to provide a scientific opinion on the safety of breast implants in relation to anaplastic large cell lymphoma (ALCL). There are several types of textured breast implants; surface textures of breast implants are not all manufactured in the same way, and breast implants with diverse surface textures may also present different benefits. The magnitude of the risk per type of textured implant is difficult to establish due to the low incidence of the breast implants associated anaplastic large cell lymphoma (BIA-ALCL). Therefore, risk assessments per implant type are needed. Overall SCHEER considers that there is a moderate weight of evidence for a causal relationship between textured breast implants and BIA-ALCL, particularly in relation to implants with an intermediate to high surface roughness.The pathogenic mechanisms are not fully elucidated; current hypotheses include genetic drivers, chronic inflammation resulting either from bacterial contamination, shell shedding of particulates, or shell surface characteristics leading to friction, or by implant associated reactive compounds. Reporting of new BIA-ALCL cases by the national clinical registries is critically important to obtain a better estimate of the risk of BIA-ALCL for patients with a breast implant.
KW - Anaplastic large cell lymphoma
KW - BIA-ALCL
KW - Breast implants
KW - Cancer
UR - http://www.scopus.com/inward/record.url?scp=85109863244&partnerID=8YFLogxK
U2 - 10.1016/j.yrtph.2021.104982
DO - 10.1016/j.yrtph.2021.104982
M3 - Comment/debate
C2 - 34214611
AN - SCOPUS:85109863244
SN - 0273-2300
VL - 125
SP - 1
EP - 4
JO - Regulatory Toxicology and Pharmacology
JF - Regulatory Toxicology and Pharmacology
M1 - 104982
ER -